Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Pfizer
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:CEO |
gptkb:Ted_W._Love
|
| gptkbp:focus |
treatments for sickle cell disease
|
| gptkbp:foundedYear |
2011
|
| gptkbp:founder |
gptkb:Ted_W._Love
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Global Blood Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Oxbryta
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:GBT
|
| gptkbp:website |
https://www.gbt.com/
|
| gptkbp:bfsParent |
gptkb:Third_Rock_Ventures
|
| gptkbp:bfsLayer |
6
|